ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help

|
|
|
|

Trending News

Guarding Against the Dangers of Vitamin D Deficiency

Omega-3 fatty acids, vitamin D may control brain serotonin, affecting behavior and psychiatric disor...

Fatigue & Fibro Fog: Could You Have a B-12 Deficiency?

How Glutathione Can Save Your Life

New Dietary Guidelines Reverse Flawed Recommendations on Cholesterol

Long term antibiotic therapy may be an effective treatment for children co-morbid with Lyme disease ...

Anticancer Properties Of Saffron

Beyond Depression... SAMe Broad-Spectrum Protection Against Disorders Of Aging

BPA exposure linked to autism spectrum disorder, study reports

Omega-3 Fatty Acids Appear to Protect Damaged Heart After Heart Attack

 
Print Page
Email Article

Another look at esreboxetine: 4th Rx alternative for fibromyalgia?

  [ 51 votes ]   [ Discuss This Article ]
www.ProHealth.com • July 26, 2012


A paper published in the July 2012 issue of Arthritis & Rheumatism...
Suggests a renewed investment interest by Pfizer Inc. in trials of its investigational drug esreboxetine as an FM therapy. (See “Safety and efficacy of esreboxetine in patients with Fibromyalgia: A 14-week, randomized, double-blind, placebo-controlled, multicenter clinical trial,” by University of Cincinnati fibromyalgia researcher Lesley M Arnold, MD, and a team at the UK-based Pfizer Global Research and Development organization.) 

For specifics not offered in the abstract of this fee-based paper...
See MedPageToday's physician CME report (“Novel Drug Helped in Fibromyalgia”).

By way of background, in Feb 2009...
Pfizer announced that they were discontinuing phase 3 trials of esreboxetine after their review of existing phase 2 trial data indicated the drug was unlikely to “provide meaningful benefit to patients beyond” other fibromyalgia Rx therapies that were already FDA approved (including Pfizer’s Lyrica, aka pregabalin). The average pain score improvement in trials of the drugs had been in the neighborhood of 30% or more, about what the new Arnold, et al. paper reports.

Now, however, at least two factors have entered the mix:

• The big three FDA approved fibromyalgia drugs will be coming off patent starting Oct 2013 with Lyrica, opening this huge multi-billion-dollar market to competition from generally lower price generics. For example, on July 5, the FDA approved marketing of a generic pregabalin product by Lupin Pharmaceuticals. At the same time, industry analysts predict "huge market opportunities" for pharmaceutical companies owing to increased FM awareness, diagnosis rates, and market penetration. 

• And second, it is suggested that the new research reflects physician/patient experience over the past few years demonstrating that responses to/side effects of the approved drugs – and to different combinations of those drugs – differ, sometimes significantly, from patient to patient. A factor that may overcome regulatory preference for a focus on drugs to treat unmet needs.

Currently, for example, a trial at the University of Utah is recruiting fibro patients to determine if differences in blood biomarkers can be linked to different responses to Lyrica (pregabalin) therapy.

Each of the approved drugs - and reboxetine - involves a different mechanism of action (albeit sometimes not entirely understood).
 
• Unlike the three currently approved drugs, esreboxetine is “a highly-selective norepinephrine reuptake inhibitor”: that is, it concentrates only norepinephrine in the brain.

• Savella (milnacipran) and Cymbalta (duloxetine) concentrate both serotonin and norepinephrine, though by different means.

• Lyrica (pregabalin) is said to decrease the release of the neurotransmitters substance P and glutamate, and “restore” release of norepinephrine.

So overall it seems fibromyalgia and neuropathic pain patients and their physicians can expect to see continued FM drug research, by Dr. Arnold at the University of Cincinnati and others.



Please Discuss This Article:   Post a Comment 



[ Be the first to comment on this article ]




 
Free Chronic Fatigue Syndrome and Fibromyalgia Newsletters
Subscribe to
Our FREE
Newsletter
Subscribe Now!
Receive up-to-date ME/CFS & Fibromyalgia treatment and research news
 Privacy Guaranteed  |  View Archives

Save on Vitamins and Supplements

Featured Products

Optimized Curcumin Longvida® by ProHealth Optimized Curcumin Longvida® by ProHealth
Supports Cognition, Memory & Overall Health
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Vitamin D3 Extreme™ by ProHealth Vitamin D3 Extreme™ by ProHealth
50,000 IU Vitamin D3 - Prescription Strength
FibroSleep™ by ProHealth FibroSleep™ by ProHealth
The All-in-One Natural Sleep Aid
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils

Natural Remedies

Research Links Green Tea to Weight Loss Research Links Green Tea to Weight Loss
The Most Powerful Natural Antioxidant Discovered to Date - Hydroxytyrosol The Most Powerful Natural Antioxidant Discovered to Date - Hydroxytyrosol
The Big Blue Fish that Helps Chase the Blues Away The Big Blue Fish that Helps Chase the Blues Away
Soothe, Heal and Regulate Your Digestive System with Nutrient-Rich Aloe Vera Soothe, Heal and Regulate Your Digestive System with Nutrient-Rich Aloe Vera
"It's Not Easy Being Green" - But It Is Healthy

FIBROMYALGIA RESOURCES
What is Fibromyalgia?
Fibromyalgia Diagnosis
Fibromyalgia Symptoms
Fibromyalgia Treatments
| CFS RESOURCES
What is CFS?
ME/CFS Diagnosis
ME/CFS Symptoms
ME/CFS Treatments
| FORUMS
Fibromyalgia
ME/CFS
ADVANCED MEDICAL LABS
WHOLESALE  |  AFFILIATES
GUARANTEE  |  PRIVACY
CONTACT US
LIBRARY
RSS
SITE MAP
ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus
Credit Card Processing